Autoimmunity and inflammation are controlled in part by regulatory B (Breg) cells, including the recently identified IL-10-competent B10 cell subset that represents 1%-3% of mouse spleen B cells. In this study, the influence of irradiation on Breg/B10 cell generation and IL-10 production mediated by TLR9 signaling pathways was investigated. Spleen and peritoneal cavity Breg/B10 cell frequencies were significantly expanded three weeks after sub-total body irradiation (sub-TBI, 5 Gy or 10 Gy) in adult male wild type (WT) C57BL/6(B6) mice but not in TLR9 −/− mice. TLR9 agonist ODN1826 stimulation in vitro for 5 h induced more B10 cells to express cytoplasmic IL-10 in sub-TBI WT mice than in TLR9 −/− mice. Prolonged ODN1826 stimulation (48 h) induced additional spleen CD19 hi CD5 + CD1d hi B cells to express IL-10. TLR9-dependent signaling molecules, MyD88, TRAF6 and IRF8 are involved in sub-TBI induced Breg/B10 cells development and expansion. Furthermore, using a mouse model for multiple sclerosis, we show here that sub-TBI induced Breg/B10 cells dramatically inhibit disease onset and severity when transferred into mice with established experimental autoimmune encephalomyelitis (EAE). Adoptively transferred sub-TBI induced Breg cells significantly suppress inflammatory T cell responses of TH17 and TH1 types in EAE mice. In conclusion, sub-TBI can drive Breg/B10 cell development and expansion, which could be used as a novel tool for suppressing undesirable immunity. The ex vivo expansion and reinfusion of autologous Breg/B10 cells may provide a novel and effective in vivo treatment for severe autoimmune diseases that are resistant to current therapies.
Introduction
B cell-negative regulation of immune responses has been demonstrated in a variety of mouse models of autoimmunity and inflammation Fillatreau et al., 2002;  Abbreviations: Breg, regulatory B cell; B10 cell, IL-10-producing B cell; EAE, experimental autoimmune encephalomyelitis; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; MyD88, myeloid differentiation primary response gene 88; Sub-TBI, sub-total body irradiation; TRIF, Toll-IL-1R domain-containing adapter-inducing IFN-␤; WT, wild-type.
* Corresponding author at: Deping Han, now at Shanghai Biotecan Diagnostics Co.
Ltd, Shanghai 201030, People' Republic of China. E-mail address: han18305956512@sina.com (D. Han). 1 Jinsheng Hong and Jie Fang contributed equally to this work and share first authorship. Matsushita et al., 2008; Rosser and Mauri, 2015; Watanabe et al., 2007) . The absence or loss of negative regulatory B (Breg) cells exacerbates disease symptoms in animal models of autoimmunity and inflammation, such as, experimental autoimmune encephalomyelitis (EAE), contact hypersensitivity (CHS) and collagen-induced arthritis (CIA) Watanabe et al., 2007; Yanaba et al., 2008) . Furthermore, Interleukin-10 (IL-10)-producing regulatory B cells (B10 cells) down regulate autoimmune disease initiation, onset, or severity in EAE (Fillatreau et al., 2002; Matsushita et al., 2008) , CIA , CHS (Mauri et al., 2003; Watanabe et al., 2007) , and inflammatory bowel disease (Ansary et al., 2014) . Although the identification of B cell subsets with negative regulatory functions and the definition of their mechanisms of action are recent events, the important negative regulatory roles of B cells in immune responses are now broadly recognized (Candando et al., 2014; DiLillo et al., 2010; Kalampokis et al., 2013; Mauri and Bosma, 2012) . A variety of regulatory B cell subsets have been described. B10 cells are the most widely studied regulatory B cell subset (Candando et al., 2014; DiLillo et al., 2010; Kalampokis et al., 2013; Mauri and Bosma, 2012) . B10 cells exert a variety of IL-10-dependent regulatory effects and are potentially involved in autoimmune disease. Both human and mouse IL-10 exhibit numerous pleiotrophic activities in vitro and in vivo, including suppression of both Th1 and Th2 polarization and inhibition of antigen presentation and proinflammatory cytokine production by dendritic cells, monocytes, and macrophages.
However, only a small portion of B cells (1-3% of spleen B cells in wild type C57BL/6 mice) produce IL-10 following PMA and ionomycin stimulation, implying that not all B cells are competent to produce IL-10. Various types of Breg found in the spleens of naïve mice including those of the CD19 hi CD5 + CD1d hi Breg cells, the marginal zone B cells (MZB, CD19 + CD21 + CD23 + ), the transitional 2-marginal zone precursor B cells (T2-MZP, CD19 + CD23 + IgM + ) and B1 lineage (B1a, CD5 + CD11b + ) (Candando et al., 2014; DiLillo et al., 2010; Kalampokis et al., 2013; Mauri and Bosma, 2012) . Combination of intracellular cytokine staining with flow cytometric phenotyping shows that mouse spleen B10 cells are enriched within the small CD1d hi CD5 + B cell subset, where they represent 15-20% of the cells in C57BL/6 mice (Calderon-Gomez et al., 2011; Kalampokis et al., 2013) . Expanding B10 cells ex vivo appears more preferable than in vivo. B10 cell expansion by nonspecific agents because it offers a potential therapy without the risk of undesirable nonspecific off-target effects. However, ex vivo B10 cell expansion brings new challenges associated with methods and magnitude of the expansion as well as time it takes to generate B10 numbers that will be sufficient for therapeutic use. Large numbers of regulatory B cells have been successfully generated in mice by means of genetic manipulation of immature B cells through lentiviral transfection or stimulation with IL-21 (Calderon-Gomez et al., 2011) . These cells were effective in treating EAE. However, although these methods can efficiently generate large numbers of regulatory B cells ex vivo, concerns remain about administering infusions of lentivirus-infected B cells to humans (with retroviral and infectious potential). Safety concerns thereby limit the use of infectious agents in manipulating human cells, which could render this approach inappropriate for use in humans.
To suppress ongoing autoimmune diseases in mice B cells must be activated via B cell receptor (BCR) for antigen, Toll-like-receptors (TLRs) and CD40, which result in sustained production of the immunosuppressive cytokine IL-10 (Gray et al., 2007; van der Vlugt et al., 2014; Yanaba et al., 2009 ). These activation pathways may therefore be useful to produce large quantity of therapeutic Breg cells.
Ionizing radiation, including X-rays, gamma rays, and heavy ions, induces damages in the cellular DNA, which lead to the activation of the DNA damage induced response and to transient or permanent cell cycle arrest, and/or cell death, respectively. In the response to irradiation, the hematopoietic system is extremely vulnerable to radiation. B-lymphocytes are ultrasensitive to radiation induced DNA damage (Jackson and Bartek, 2009; Nishii et al., 1998) . They also regenerate and differentiate quickly in a preprogrammed fashion. We have explored the effect of subtotal body irradiation (sub-TBI) on B-lymphocyte precursors in mouse bone marrow (Han et al., 2012) , but the effect of irradiation on Breg/B10 cell generation and IL-10 production are still unknown. Since necrotic cells have lost their membrane integrity, formerly hidden molecules such as DNA, chaperones, and proteins involved in stabilization of the DNA are released after irradiation (Beyer et al., 2012) . These cell death products, by providing simultaneously both antigenic and nonantigenic stimuli and acting on their corresponding receptors such as TLR4/TLR9, may represent one of the physiologic triggers for Breg/B10 cell development. The identification of such effect of irradiation will provide additional insights into Breg cell development that may prove invaluable for the future manipulation of Breg cells for treating autoimmune disease. In this study, the influence of irradiation on Breg/B10 cell generation and IL-10 production mediated by TLR9 signaling pathways was investigated. Furthermore, using a mouse model for multiple sclerosis, we show here that sub-TBI can drive B10 cell development and expansion, and generate producing IL-10 B10 effect cells that dramatically inhibit disease symptoms when transferred into mice with established EAE.
Material and methods

Mice
Adult male wild type C57BL/6 (B6) mice were obtained from Sipper BK Experimental Animals Co. (Shanghai, China). B6. TLR9-knockout mice (B6. TLR9 −/− ) were purchased from Jackson Laboratories (Bar Harbor, ME). All mice were housed in a SPF facility, and used at 6-8 weeks of age. All procedures were approved by the Scientific Investigation Board of the Fujian Medical University in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. At the time of data collection, mice were humanely euthanized by CO 2 inhalation.
Antibodies
The antibodies used in this study were as follows: FITC-, PE-, PE-Cy5-, PE-Cy7-, or APC-conjugated CD1d (1B1), CD5 (53-7.3), CD19 (1D3), CD21 (7G6), CD23 (B3B4), CD25 (7D4), CD40L (TRAP1), CD86 (GL1), IgM (1D12), pSTAT3 Y705 (D3A7), TIM-1(R4-22), ROR␥t (Q21-559)and IL-10 (JES5-16E3) mAbs were from BD Biosciences (San Jose, CA). Antibodies for MyD88, TRAF6, IRF8 and NF-B (p65) were from Abcam (Cambridge, UK). Antibodies for ␤-actin were obtained from Sigma-Aldrich (St. Louis, MO, USA). APC-conjugated TLR9 (M9.D6) and IL-17A (17B7) mAb were from eBioscience (San Diego, CA). Background staining was assessed using non-reactive, isotype-matched control mAbs (Caltag Laboratories, San Francisco, CA). For two-to four-color immunofluorescence analysis, single cell suspensions (10 6 cells) were stained at 4 • C using predetermined optimal mAb concentrations for 20 min as described (Han et al., 2012) . Blood erythrocytes were lysed after staining using FACS TM Lysing Solution (Becton Dickinson, San Jose, CA).
B cell isolation, immunofluorescence analysis and cell sorting
B cells were isolated from WT C57BL/6 mice with or without sub-TBI (5 Gy or 10 Gy). Suspensions of single splenocytes with >90% cell viability as determined by trypan blue exclusion were prepared. Cell numbers were quantified using a hemocytometer, with relative lymphocyte percentages among viable cells (based on scatter properties) determined by flow cytometry analysis. CD19-mAb coated microbeads (Miltenyi Biotech) were used to purify spleen B cells by positive selection following the manufacturer's instructions. When necessary, the cells were enriched a second time using a fresh MACS column to obtain >99% purity.
Single cell suspensions were stained on ice using predetermined optimal concentrations of each Ab for 20-60 min, and fixed as described (Han et al., 2012) . Cells with the light scatter properties of lymphocytes were analyzed by 2-4 color immunofluorescence staining and FACS Area III flow cytometer (Becton Dickinson, San Jose, CA). Dead cells were excluded from the analysis based on their forward-and side-light scatter properties and the use of LIVE/DEAD Fixable Dead Cell Stain Kits (Invitrogen-Molecular Probes, Carlsbad, CA). All histograms are shown on a 4 decade logarithmic scale, with gates shown to indicate background isotype-matched control mAb staining set with <2% of the cells being positive. Background staining was determined using unreactive isotype-matched control mAbs (Caltag Laboratories, San Francisco, CA) with gates positioned to exclude ≥98% of unreactive cells. Spleen CD19 hi CD5 + CD1d hi Breg cells were isolated using a FACS Area III flow cytometer (Becton Dickinson, San Jose, CA) with ∼80%-95% purities.
Real-time PCR
Real-time PCR was performed in the Applied Biosystems 7500 Real-Time PCR System software using SYBR GREEN PCR MasterMix (Qiagen). PCR was performed under the following conditions: initial denaturation at 95 • C for 15 min and 37 cycles of 95 • C for 30 s, 60 • C for 30 s, and 72 • C for 20 s. The generation of specific PCR products was confirmed by melting curve analysis. Each reaction was run in triplicate. The expression of TLR4 or TLR9 was normalized against ␤-actin by the comparative threshold cycle (ct) method using the following formula: fold difference in expression = 2 -( ctoftargetgene-ctofreference) . Primer sequences for real time PCR were: TLR4, 5 -GCATAGAGGTAGTTCCTAATA-3 (forward) and 5 -CACTCTTG ATTGCAGTTTCAA-3 (reverse); TLR9, 5 -GAATCCTCCATCTCCCAACAT-3 (forward) and 5 -CCAGAGTCTCAGCCAGCACT-3 (reverse); ␤-actin, 5 -GCCAACACAGTGCTGTCT-3 (forward), and 5 -AGGAGCAATGATCTTGATCTT-3 (reverse).
Analysis of IL-10 production
Intracellular IL-10 analysis by flow cytometry was as described (Yanaba et al., 2009) . Briefly, isolated splenocytes were resuspended (2 × 10 6 cells/ml) in complete medium [RPMI 1640 media containing 10% FCS, 200 g/ml penicillin, 200 U/ml streptomycin, 4 mM l-Glutamine, and 5 × 10 −5 M 2-mercaptoethanol (all from Gibco, Carlsbad, CA)] and incubated with LPS (10 g/ml, Escherichia coli serotype 0111: B4, Sigma-Aldrich) and/or CpG (ODN 1826, 10 g/ml; Invivogen), PMA (50 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma), and monensin (2 M; eBioscience) for 5 h, in 24-well flat-bottom plates. In some experiments, the cells were incubated for 48 h with LPS (10 g/ml) and/or ODN 1826 (10 g/ml), PMA (50 ng/ml), ionomycin (500 ng/ml), with or without monensin (2 M; eBioscience) for 5 h. For IL-10 or TLR9 detection, Fc receptors were blocked with mouse Fc receptor mAb (2.4G2; BD PharMingen) with dead cells detected by using a LIVE/DEAD ® Fixable Green Dead Cell Stain Kit (InvitrogenMolecular Probes) before cell surface staining. Stained cells were fixed and permeabilized using a Cytofix/Cytoperm kit (BD PharMingen) according to the manufacturer's instructions and stained with anti-IL-10 mAb or anti-TLR9 mAb. Secreted IL-10 was quantified by ELISA. Purified B cells (4 × 10 5 ) were cultured in 0.2 ml of complete medium in a 96-well flatbottom tissue culture plates. Culture supernatant fluid IL-10 concentrations were quantified using Murine IL-10 ELISA kits (R&D Systems, Minneapolis, MN, USA) following the manufacturer's protocols. All assays were carried out using triplicate samples.
Western blot assay
B cells isolated from WT C57BL/6 mice with or without sub-TBI (5 Gy or 10 Gy) were lyzed in lysis buffer (Cell Signaling Technology) for 30 min on ice. Then a BCA kit (Pierce Biotechnology, Rockford, IL, USA) was used to determine the protein concentration of lysates. Cell extracts were separated by 10% sodium dodecylsulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane. The blot was probed with antibodies specific for MyD88, TRAF6, IRF8, NFB and ␤-actin mAb followed by peroxidase labeled 2nd antibodies. Signals were developed using an enhanced chemiluminescence detection reagent. The relative protein level was determined with band intensities compared with ␤-actin using the computer program Quantity One (Bio-Rad).
EAE induction
EAE was induced in 6-to 8-week-old female B6 mice by subcutaneous immunization with 100 g of MOG 35-55 peptide (MEVGWYRSPFSRVVHLYRNGK; NeoMPS, San Diego, CA) emulsified in CFA containing 200 g of heat-killed Mycobacterium tuberculosis H37RA (Difco, Detroit, MI) on day 0. Additionally, mice received 200 ng of pertussis toxin (List Biological Laboratories, Campbell, CA) i.p. in 0.5 ml of PBS on day 0 and 2. Clinical signs of disease were assessed daily for up to 30 days after immunization with a 0-5 point scoring system: 0, no detectable sign of EAE; 1, loss of tail tone; 2, hind-limb weakness; 3, hind-limb paralysis; 4, hind-limb and forelimb paralysis; 5, moribund or dead.
Adoptive transfer experiments
CD19 + splenocytes were purified from WT or TLR9 −/− C57BL/6 mice. CD19 hi CD5 + CD1d hi Breg cells were sorted with purities of 90-95% and cultured with PBS, LPS, ODN1826 or ODN1826 + LPS for 48 h with PMA and ionomycin added during the final 5 h of culture. One day before MOG 35-55 immunization, the B10 cells (1 × 10 6 ) were transferred i.v. into recipient mice. In some cases, CD19 + splenocytes were purified from WT C57BL/6 mice with or without sub-TBI (5 Gy) 3 weeks ago and cultured with PBS or ODN1826 for 48 h with PMA and ionomycin added during the final 5 h of culture. One day before MOG 35-55 immunization or 7 or 14 days after MOG 35-55 immunization, the B10 cells (1 × 10 6 ) were immediately transferred i.v. into recipient mice. Mice were scored daily thereafter for disease severity.
Intracellular staining for TH17
Splenocytes were prepared from mice 16 days after EAE induction. These mice had been treated on day −1, 7 and 14 with ODN1826 (48 h) and PMA+ ionomycin (5 h) stimulated WT mice spleen B10 cells, Sub-TBI induced B10 cells, or with PBS alone. Cells were seeded at 2 × 10 6 /well in flat-bottom 48-well plates, and restimulated with MOG 35-55 (20 g/ml) in presence of Golgistop as recommended (BD Pharmingen). After 12 h, surface and intracellular cytokine staining was done using mAbs reactive with IL-17A and Cytofix/Cytoperm kit (BD biosciences).
Statistical analysis
All experiments were independently repeated at least three times. Results are given as mean ± SEM. Statistical significance was determined by Student t-test. Comparisons between two groups were done using Student t-test analysis. Multiple comparisons were done with a one-way ANOVA, followed by Fisher's least significant difference analysis, or done with Kruskal-Wallis tests, with a P value of 0.05 or less considered statistically significant.
Results
Effect of sub-TBI on B cells and Breg/B10 cells
To investigate effects of irradiation damage on B cells and the pattern of regeneration of these cells, frequencies and numbers of CD19 + B cells, CD19 hi CD5 + CD1d hi Breg cells and IL-10-producing B (B10) cells in spleen of wild type (WT) and TLR9 −/− C57BL/6 mice were assessed. Fig. 1 A shows that CD19 + B cells in the "lymphocyte −/− C57BL/6 mice irradiated with 0 Gy, 5 Gy or 10 Gy. Cells were stained with CD19, CD5, and CD1d mAbs, and then permeabilized, and stained using IL-10 mAb for flow cytometry analysis. area" were declined dramatically and inversely correlated with the radiation dose used. They were reduced to the nadir in the first week after sub-TBI, but then recovered afterwards, though the levels were still lower than those in the non-irradiated controls at 4 weeks after sub-TBI. This phenomenon was observed both in WT and TLR9 −/− C57BL/6 mice. The frequency of CD19 hi CD5 + CD1d hi Breg, CD19 + CD21 + CD23 − (MZB), CD19 + CD23 + IgM + (T2-MZP) and CD5 + CD11b + (B1a) cells in the spleen were reduced obviously in the first week after irradiation, but then regenerated gradually (Fig. 1B-E) . As compared with non-irradiated control, the frequencies of spleen B10 cells were 3-fold-or 2.2-fold higher in 5-Gy and 10-Gy WT mice 3 weeks after sub-TBI, respectively (P < 0.01). By contrast, these phenomena were not appeared in TLR9 −/− mice.
Effect of irradiation on the expression of TLR9 in mice B10 cells
To further prove TLR9 involvement in irradiation related regulation of B10 cells production, the expression of TLR9 was analyzed with RT-PCR and FCM. Compared with non-irradiated mice, TLR9 and TLR4 expression on CD19 hi CD5 + CD1d hi B10 cells of mouse spleen was significantly decreased 1 week after 5-Gy or 10-Gy sub-TBI. However, the expression of TLR9 on B10 cells of spleen was enhanced (2.5-fold or 2.0-fold, respectively) in mice 3-4 weeks after sub-TBI relatively to those in non-irradiated mice ( Fig. 2A and  B) .
In addition, TLR9 expression on spleen B10 cells in 3 weeks after 5-Gy sub-TBI mice was increased significantly after 5 h of LPIM stimulation relative to wild type B cells in mouse spleen (Fig. 2C) . Prolonged B-cell stimulation with LPS, ODN1826 or LPS plus ODN1826 (48 h) and 5 h of PIM stimulation induced further increase in the expression of TLR9 (about 1.5-fold in spleen) compared with non-irradiated mice control (P < 0.05; Fig. 2D ).
To further confirm that TLR9/MyD88 signaling pathway are involved in sub-TBI induced B10 cell development and expansion, we examined the expression of TLR9-dependent signaling molecules, MyD88, TRAF6, IRF8 and NF-B on spleen B10 cells. We found that stimulation for 48 h with ODN1826 alone induce slight increase expression of these signal molecules in wild type mouse spleen B10 cells. However, expressions of MyD88, TRAF6, IRF8 and NF-B on spleen B10 cells from 5-Gy sub-TBI mice 3 weeks after irradiationwere increased evidently after stimulated 48 h with ODN1826 (Fig. 2E) . These results confirmed that TLR9-dependent signal pathway plays a key role in the process of sub-TBI induced B10 cells development and expansion.
Effect of sub-TBI on the B10 cell IL-10 production and secretion
Purified spleen CD19 + B cells from non-irradiated or irradiated WT or TLR9 −/− mice (three weeks after 5 Gy sub-TBI) were cultured in medium alone or containing LPS or TLR9 agonist ODN1826. To visualize IL-10-competent B (B10) cells, LPS and/or ODN1826, PMA, ionomycin and monensin (L + PIM) were added to the cultures for indicated time period before the cells were stained for cell surface CD19 and cytoplasmic IL-10 expression, and analyzed by flow cytometry (FCM). Compared to the B10-cell frequencies in control media group (0.70% ± 0.20%), mean B10-cell frequencies in WT mice spleen CD19 + B cells after 5 h of L + PIM, ODN1826 + PIM and ODN1826 + LPS + PIM stimulation were cells within the indicated gates among total CD19 + B cells in spleen. Bar graphs indicate mean (±SEM) percentages and numbers in one of three independent experiments with 5 mice in each group.
Fig. 2. Effect of irradiation on TLR9 expression on CD19
hi CD5 + CD1d hi B10 cells. (A and B) Splenocytes were derived from wild type (WT) C57BL/6 mice after irradiated with 0 Gy, 5 Gy or 10 Gy. CD19 hi CD5 + CD1d hi B10 cells were sorted and then RT-PCR was performed using specific primers for TLR4 or TLR9, and stained using TLR4 or TLR9 mAbs with flow cytometry analysis. In some cases, CD19 + splenocytes were purified from WT mice with or without sub-TBI (5 Gy) 3 weeks ago. CD19 hi CD5 + CD1d hi B10 cells were sorted and cultured with media alone, LPS+ PMA, ionomycin and monensin (PIM) (LPIM), TLR9 agonist ODN1826 + PIM, or ODN1826 + LPIM for the times indicated. Cells were stained with CD19, CD5, CD1d, and TLR9 mAb with flow cytometry analysis (C and D). Bar graphs indicate mean (±SEM) percentages in one of three independent experiments with 5 mice in each group. (E) Representative immunoblots and relative fold expression showing expressions of MyD88, TRAF6, IRF8 and NF-B in Breg cells derived from WT mice with or without sub-TBI (5 Gy) 3 weeks ago and stimulated with PBS, LPS, ODN1826 or ODN1826 + LPS for 48 h with PIM added during the final 5 h of culture. 2.50% ± 0.30%, 1.37% ± 0.20% and 2.70% ± 0.43% respectively. B10-cell frequencies in WT mice spleen three weeks after 5 Gy sub-TBI were obviously higher after 5 h' culture with control media alone (1.89% ± 0.41%), or with L + PIM (10.30% ± 0.53%), ODN1826 + PIM (4.72% ± 0.48%) and ODN1826 + LPS + PIM (14.56 ± 1.04%), respectively ( Fig. 3A and B) . In addition, to assess B cell IL-10 secretion, spleen CD19 + B cells were first treated with LPS and/or ODN1826. IL-10 levels in the conditional medium were then determined by ELISA. LPS stimulation of WT or TLR9 −/− mice spleen B cells for 5 h induced more IL-10 secretion than un-stimulated cells. ODN1826 stimulation just enhanced spleen B10 cell IL-10 secretion in WT mice, but not in TLR9 −/− mice (Fig. 3C ). In addition, the frequencies of spleen B10-cells were also assessed after 48 h of culture with LPS and/or ODN1826 and 5 h of PIM stimulation. Prolonged B-cell stimulation induced significant increase in both B10-cell frequencies ( Fig. 3D and E) and IL-10 secretion (Fig. 3F ) in WT mice, but not in TLR9 −/− mice. Furthermore, B cells from WT mice spleen three weeks after sub-TBI (5 Gy), showed increased B10-cell frequencies after stimulated with LPS, ODN1826 or LPS plus ODN1826 (48 h) and 5 h of PIM stimulation (3.5-fold, 2.0-fold; or 4.0-fold, respectively) compared with non-irradiated mice. IL-10 production also increased obviously (P < 0.01; Fig. 3F ). In addition, the activation markers such as CD25, CD40L, CD86 and TIM-1 expression on B10-cells were increased after stimulated with LPIM 5 h or 48 h (Fig. 3G) .
Sub-TBI induced B10 cell amplification reduce EAE disease severity
To determine whether TLR9 is necessary for B10 cells to regulate EAE responses, spleen CD19 hi CD5 + CD1d hi B10 cells were purified from naive wild type or TLR9 −/− mice and activated with LPS or ODN1826 (48 h) and, PMA and ionomycin stimulation (5 h). 10 6 cells per recipient were adoptively transferred into C57BL/J mice 24 h before immunization with MOG . Transferring LPS, ODN1826 or LPS + ODN1826 activated WT B10 cells into EAE mice could reduce EAE severity (cumulative EAE score, 31.7 ± 3.5, 34.6 ± 3.8, 26.4 ± 4.0, respectively, Fig. 4A ) in comparison with PBS-treated littermates (45.6 ± 4.5). By contrast, the adoptive transfer of activated TLR9 −/− B10 cells did not evidently affect EAE severity (cumulative EAE score, 39.7 ± 4.6, 41.6 ± 4.8, 37.4 ± 4.2, respectively, Fig. 4A ) in wild type mice.
Then, we evaluated the suppressive capacity of sub-TBI induced WT B10 cells in EAE mice. Spleen CD19 hi CD5 + CD1d hi B10 cells were purified from sub-TBI (5 Gy, 3 weeks) or un-irradiated WT mice and activated for 48 h with ODN1826 and 5 h with PMA and ionomycin stimulation. 10 6 cells per recipient were adoptively transferred 1 day before immunization, 7 days or 14 days after immunization with MOG . We found that Sub-TBI induced B10 cells, adoptively transferred before or after disease induction, obviously reduced disease severity and improved recovery from EAE (cumulative EAE score, 8.8 ± 3.1, 23.2 ± 3.6, 35.6 ± 3.8, respectively, Fig. 4B-D) , compared to mice treated with WT B10 cells (26.4 ± 4.0, 33.4 ± 4.1, 41.3 ± 4.3, respectively), or to PBS treated mice (45.6 ± 4.5). However, inhibition of disease onset was only observed when the transferred cells were given before MOG 35-55 immunization of recipients, but not on day 7 or 14 after immunization.
Adoptively transferring sub-TBI induced B10 cells suppress inflammatory T cell responses of TH17 in EAE mice
To identify how Sub-TBI induced B10 cells facilitate remission from EAE, we investigated encephalitogenic T responses 16 days after EAE induction in mice treated or not with Sub-TBI induced B10 cells at different time points. Following adoptive transfer of ODN1826 activated Sub-TBI induced B10 cells, the frequencies of + splenocytes were purified from wild type (WT) or TLR9 −/− C57BL/6 mice. CD19 hi CD5 + CD1d hi B10 cells were sorted and cultured with media alone, LPS, TLR9 agonist ODN1826 + LPS for 48 h with PIM added during the final 5 h of culture to induce B10 cell maturation. The adoptive transfer of purified spleen CD19 hi CD5 + CD1d hi B10 cells requires TLR9 expression to reduce EAE disease severity. (B-D) In some cases, CD19 + splenocytes were purified from WT C57BL/6 mice with or without sub-TBI (5 Gy) 3 weeks ago. CD19 hi CD5 + CD1d hi B10 cells were sorted and cultured with ODN1826 for 48 h with PIM added during the final 5 h of culture. One day before MOG35-55immunizations (B) or 7 or 14 days after MOG35-55 immunization (C and D) as indicated (arrowheads), wild type recipient mice were given either PBS or different treated B10 cells. Mice were scored daily thereafter for disease severity. The top two graphs show data from the same experiment, but were separated to facilitate visualization of the overlapping curves. Values represent mean (± SEM) symptom scores from ≥3 mice in each group, with similar results obtained in three independent experiments. Significant differences between sample means are indicated; *, P < 0.05, **, P < 0.01 (versus white circle). CD4 + IL-17 + (TH17) cells and the production of IL-17A were reduced compared with PBS or WT B10 cells treated EAE mice (Fig. 5A-C) . Furthermore, the expression of pSTAT3 Y705 and ROR␥t, which were critical for the production of IL-17, on spleen TH17 cells 16 days after EAE induction, were decreased evidently after adoptive transfer of Sub-TBI induced B10 cells (Fig. 5D ).
Discussion
B-lymphocyte precursors are ultrasensitive to radiation induced DNA damage (Jackson and Bartek, 2009; Nishii et al., 1998) . They also regenerate and differentiate quickly in a preprogrammed fashion. We have reported the transition pattern and mechanism of B-lymphocyte precursors in regenerated mouse bone marrow after sub-TBI (Han et al., 2012) . This study sought to explore the impact of ionizing radiation on B-cell development via an examination of populations of B cells and Breg/B10 cells within spleen as a function of radiation doses and times in a sub-TBI mouse model. The results demonstrated that there was a significant radiation dose-related reduction in the number of B cells and B10 cells 1 and 2 weeks after sub-TBI, but then they were recovery gradually 3 and 4 weeks after sub-TBI. Specifically, the number of CD19 hi CD5 + CD1d hi Breg, CD19 + CD21 + CD23 − MZB, CD19 + CD23 + IgM + T2-MZP and CD5 + CD11b + B1a cells not only returned to the normal level and far exceeds the normal level 3 and 4 weeks after sub-TBI in the spleen of wild type (WT) but not in TLR9 −/− mice. Sub-TBI also induced a 3-fold increase in CD19 + IL-10 + B cells within the spleen that is enriched for B10pro and B10 cells, but it did not significantly induce the number of CD19 + IL-10 + B cells in TLR9 −/− mice (Fig. 1) . These results suggest that TLR9 would involve in the induction of B10 cells by sub-TBI. In fact, the involvement of TLR signals in B10-cell IL-10 production was recently demonstrated. B10 cells can be driven to produce IL-10 by TLR4 (LPS) or TLR9 (CpG oligonucleotides) ligands (Yanaba et al., 2009) . Numbers of B cells with the capacity to produce IL-10 are equivalent in wild type and TLR9 −/− mice when their maturation or IL-10 production are measured following PMA plus ionomycin stimulation, demonstrating that B10 cells are present at normal frequencies in TLR9 −/− mice. But, B10-cell frequencies in WT mice spleen three weeks after 5 Gy sub-TBI were obviously higher than un-irradiated mice. Spleen B10 cell frequencies were not significantly expanded three weeks after 5 Gy sub-TBI in TLR9 −/− mice. In vitro stimulation of spleen cells with LPS and/or ODN1826, PMA, plus ionomycin for 5 h induced more B10 cells to express cytoplasmic IL-10 in sub-TBI WT mice than in TLR9 −/− mice. Prolonged LPS and/or ODN1826 stimulation (48 h) induced additional higher spleen B10 cell frequencies and more IL-10 secretion (P < 0.01) following PMA + ionomycin stimulation.
B10 cells can be expanded for therapeutic purposes either in vivo or ex vivo. B10 cell expansion appears to be a more viable approach since some of the stimuli driving their development have been identified. It is well known that apart from necroptosis, ionizing radiation -particularly when applied in high single doses during ablative radiotherapy -can trigger necrosis, an acciden-tal, uncontrolled form of cell death as a consequence of excessive physico-chemical stress (Munoz et al., 2010; Rudner et al., 2001; Vandenabeele et al., 2010) . Moreover, secondary necrosis can occur when apoptotically dying cells are not properly and timely engulfed by neighboring cells or professional phagocytes, respectively (Eriksson and Stigbrand, 2010; Silva, 2010) . IL-10 production by B10 cells, stimulated by contact with apoptotic cells, results from the engagement of TLR9 within the B cell after recognition of DNA-containing complexes on the surface of apoptotic cells by the BCR. Cell death products may therefore represent one of the physiologic triggers for B10 cell development by providing a combination of BCR and TLR signals (Gray et al., 2007) . To further investigate whether TLR9 involved in irradiation related regulation of B10 cells production, the expression of TLR9 was analyzed with FCM. Compared with non-irradiated mice, TLR9 expression on CD19 hi CD5 + CD1d hi Breg cells of mouse spleen was significantly enhanced (2.5-fold or 2.0-fold, respectively) in mice 3-4 weeks after sub-TBI relatively to those in non-irradiated mice. These results suggest that irradiation induced up-regulation of TLR9 expression may be one reason for the expanding of B10 cells in sub-TBI mice. It has been report that TLR4 and TLR9 signaling through myeloid differentiation primary response gene 88 (MyD88) is necessary for the optimal maturation and IL-10 induction of B10pro and B10 cells following LPS stimulation and LPS or CpG stimulation, respectively (Yanaba et al., 2009 ). Our results show that CpG stimulation induced significantly enhanced expression of MyD88, TRAF6, IRF8 and NF-B in spleen B10 cells form 5-Gy sub-TBI mice that had been irradiated 3 weeks ago and stimulated with ODN1826 for 48 h, relative to non-irradiated wild type mouse spleen B cells. These results are therefore useful information for producing therapeutic regulatory B cells.
Harvesting the anti-inflammatory properties of B10 cells can provide a new approach to the treatment of autoimmunity. An early study has highlighted the effects of apoptotic cells on B cell IL-10 production, where apoptotic cells protected mice from developing collagen-induced arthritis (CIA) by the induction of IL-10-producing regulatory B cells (Gray et al., 2007) . We evaluated the suppressive capacity of sub-TBI induced B10 cells in the mouse EAE model of human MS. The transfer of LPS and/or ODN1826 activated B10 cells derived from WT mice could reduce disease severity of EAE, compared to mice treated with PBS. While ODN1826 activated TLR9 −/− B10 cells did not have such an evident effect. These results suggest that B10 cells require TLR9 expression to regulate EAE severity. In addition, adoptively transfer of ODN1826 activated sub-TBI (5 Gy 3 weeks before) induced B10 cells derived from WT mice dramatically reduced the disease severity and improved the recovery from EAE, compared to mice treated with ODN1826 activated WT B10 cells, or to PBS treated mice, even when given after the appearance of disease symptoms. However, inhibition of disease onset was only observed when the transferred cells were given before MOG 35-55 immunization of recipients, but not on day 7 or 14 after the immunization, which means that once disease is established, adoptive transfer of B10 cells does not suppress ongoing EAE. Furthermore, sub-TBI induced B10 cells transfer could significantly reduce the frequencies of CD4 + IL-17 + cytokine-positive cells among CD4 + T cells compared with WT B10 cells or PBS treated EAE mice. These results suggest that sub-TBI induced B10 cells suppress inflammatory T cell responses of TH17 in EAE mice spleen. Thereby, sub-TBI induced B10 cells appear to normally regulate acute autoimmune responses in EAE.
The important regulatory effects of B10 cells in vivo and their therapeutic potential in autoimmunity have been demonstrated in a variety of mouse models of human autoimmune disease. The current studies demonstrate that B10 cell expansion after sub-TBI, by providing cell death products simultaneously as either antigenic or nonantigenic stimuli, may represent one of the physiologic triggers for B10 cell development, and that adoptively transferred sub-TBI induced B10 cells are sufficient to blunt EAE induction and to reduced disease severity. Thus, the development of sub-TBI induced B10 cell-based therapies may be ideal for treating some autoimmune diseases. This approach appears promising since it provides an effective way of generating large numbers of B10 cells without the use of infectious agents. The development of a similar system for expanding human B10 cells is of outmost importance. This could include the isolation from sub-TBI individuals, expansion, and transfer of the expanded B10 cells back to the individuals. Other studies have also shown that the adoptive transfer of B cells can have a therapeutic benefit in the treatment of mice with EAE, type 1 diabetes, and CIA. It may also be possible to identify pathways that regulate B10 cell activation, expansion, and function, which will allow this potent B cell subset to be manipulated for therapeutic benefit.
In conclusion, Sub-TBI can drive Breg/B10 cell development and expansion, which could be used as a novel tool for suppressing undesirable immunity. The ex vivo expansion and reinfusion of autologous B10 cells may provide a novel and effective in vivo treatment for severe autoimmune diseases that are resistant to current therapies. 
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